title: Modulation of tumor hypoxia by topical formulations with vasodilators for enhancing therapy.
abstract: Tumor hypoxia is a well known therapeutic problem which contributes to radioresistance and aggressive tumor characteristics. Lack of techniques for repeated measurements of tumor oxygenation (pO(2), partial pressure of oxygen) has restricted the optimization of hypoxia modifying methods and their efficacious application with radiotherapy. We have investigated a non-invasive method to enhance tissue pO(2) of peripheral tumors using topical application of formulations with BN (Benzyl Nicotinate), a vasodilator, and have used EPR (Electron Paramagnetic Resonance) oximetry to follow its effect on tumor oxygenation.We incorporated 2.5% BN in both hydrogel and microemulsions and investigated the effects on pO(2) of subcutaneous RIF-1 (Radiation Induced Fibrosarcoma) tumors in C3H mice. The experiments were repeated for five consecutive days. The topical application of BN in hydrogel led to a significant increase from a pre-treatment pO(2) of 9.3 mmHg to 11 - 16 mmHg at 30 - 50 min on day 1. However, the magnitude and the time of significant increase in pO(2) decreased with repeated topical applications. The BN in a microemulsion resulted in a significant increase from a baseline pO(2) of 8.8 mmHg to 13 - 18 mmHg at 10 - 50 min on day 1. Experiments repeated on subsequent days showed a decline in the magnitude of pO(2) increase on repeated applications. No significant change in tumor pO(2) was observed in experiments with formulations without BN (vehicle only).EPR oximetry was successfully used to follow the temporal changes in tumor pO(2) during repeated applications for five consecutive days. This approach can be potentially used to enhance radiotherapeutic outcome by scheduling radiation doses when an increase in tumor pO(2) is observed after topical applications of BN formulations.
authors: Laboratory of Biophysics, Jozef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia.
authors: Zrinka
authors: Z
authors: Abramovic
authors: Huagang
authors: H
authors: Hou
authors: Kristl
authors: K
authors: Julijana
authors: Marjeta
authors: M
authors: Sentjurc
authors: Jean P
authors: JP
authors: Lariviere
authors: Harold M
authors: HM
authors: Swartz
authors: Nadeem
authors: N
authors: Khan
mesh_terms: D000287:Administration, Topical; D000818:Animals; D004578:Electron Spin Resonance Spectroscopy; D005260:Female; D005354:Fibrosarcoma / Q000532:radiotherapy*; D000860:Hypoxia; D051379:Mice; D008809:Mice, Inbred C3H; D009381:Neoplasms, Radiation-Induced / Q000532:radiotherapy*; D009539:Nicotinic Acids / Q000008:administration & dosage* / Q000494:pharmacology; D010092:Oximetry; D010100:Oxygen / Q000378:metabolism*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000494:pharmacology; D012513:Sarcoma, Experimental / Q000532:radiotherapy*; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D009539:Nicotinic Acids; D011838:Radiation-Sensitizing Agents; D014665:Vasodilator Agents; C025653:nicotinic acid benzyl ester; D010100:Oxygen